Document Details

Document Type : Article In Journal 
Document Title :
Essential Thrombocythemia: Current Molecular and Therapeutic Insights
Essential Thrombocythemia: Current Molecular and Therapeutic Insights
 
Document Language : English 
Abstract : Essential thrombocythemia is one of the Philadelphia chromosome negative, clonal myeloproliferative disorders involving the hematopoietic stem cells and is characterized by elevated platelet counts and attendant thromboembolic phenomenon. A point mutation in the Janus-Activated Kinase 2 gene (JAK2V617F) accounts for nearly 50% of Essential thrombocythemia patients while about 10% have mutations in the thrombopoetin receptor (MPL) gene (MPLW515L/K). Several other genes are implicated, clearly indicating the existence of drivers both common and uncommon in the causation of Essential thrombocythemia. Genotyping for mutations will therefore be a useful diagnostic tool for detection of Janus-Activated Kinase 2 negative, MPL negative, Essential thrombocythemia patients. An integrated approach of systematic analysis leading to accurate diagnosis will enable risk stratification and institution of therapy following the World Health Organization guidelines. In addition to Janus-Activated Kinase inhibitors, a combination of agents that has anti-inflammatory properties could help prevention and/ or reversal of fibrosis. 
ISSN : 1658-5763 
Journal Name : Saudi Journal of Internal Medicine 
Volume : 5 
Issue Number : 1 
Publishing Year : 1436 AH
2015 AD 
Article Type : Article 
Added Date : Wednesday, April 20, 2016 

Researchers

Researcher Name (Arabic)Researcher Name (English)Researcher TypeDr GradeEmail
Kalamegam GauthamanGauthaman, Kalamegam Investigator  
Fatin M. Al-SayesAl-Sayes, Fatin M.Researcher  

Files

File NameTypeDescription
 38623.pdf pdf 

Back To Researches Page